Intellectual Property Disputes Relating to Generic Drugs
First written in FY2018. 2 of 5 entries say "Mitigated", first in FY2019. Latest entry: FY2025.
The whole theme swung hardest in 2025: 9 of 59 companies on the "Worse" side.
- FY2025RestatedAnnual report
「As measures to address this risk, the company is strengthening cooperation between its legal and intellectual property departments, enhancing its company-wide intellectual property management strategy, preventing intellectual property disputes and responding promptly to ongoing disputes. It is also expanding its network of external specialists with whom it can work closely when disputes arise and further strengthening those relationships.」
The company reconfirms dispute prevention and early response through cooperation between the legal and intellectual property departments, company-wide intellectual property management and collaboration with external specialists. - FY2023MitigatedAnnual report
「As measures to address this risk, the company is strengthening cooperation between its legal and intellectual property departments, enhancing its company-wide intellectual property management strategy, preventing intellectual property disputes and responding promptly to ongoing disputes. It is also expanding its network of external specialists with whom it can work closely when disputes arise and further strengthening those relationships.」
The company specifically describes its response to intellectual property dispute risk, including cooperation between the legal and intellectual property departments, a company-wide management strategy and stronger relationships with external specialists. - FY2021RestatedAnnual report
「Differences in views between the Group and intellectual property rights holders could develop into legal disputes, including petitions for invalidation trials, with the Company as plaintiff. Legal disputes could also arise on the grounds of suspected patent infringement, with the Company as defendant.」
The company reconfirms the possibility of disputes in which it may be either plaintiff or defendant concerning patents and other intellectual property rights related to generic drugs. - FY2019MitigatedAnnual report
「Bayer Yakuhin, Ltd., the appellant, withdrew its appeal in full on 31 July 2019. As a result, the first-instance judgment of the Tokyo District Court dated 12 June 2019, which dismissed the plaintiff's claims, became final and binding. The finalization of the judgment had no impact on the Group's operating results.」
The patent infringement injunction lawsuit concerning lanthanum carbonate orally disintegrating tablets is described as having been resolved with the first-instance judgment dismissing the claims becoming final and binding. - FY2018First statedAnnual report
「Differences in views between the Group and intellectual property rights holders could develop into legal disputes, including petitions for invalidation trials, with the Company as plaintiff. Legal disputes could also arise on the grounds of suspected patent infringement, with the Company as defendant.」
Although the company conducts investigations into patents and other intellectual property rights, it recognizes the possibility of disputes in which it may be either plaintiff or defendant.